Century Therapeutics (IPSC) risk factors, FY2025 10-K

Risks related to our financial position and capital requirements

1. 01We have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future51% rewritten
2. 02We have never generated revenue from product sales and may never achieve or maintain profitability36% rewritten
3. 03We will require additional funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts48% rewritten
4. 04Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates40% rewritten
5. 05Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
6. 06Changes in tax law may adversely affect us or our investors54% rewritten
7. 07Unstable market and economic conditions may have serious adverse consequences on our business, financial condition, and stock price

Risks related to our business and industry

1. 08We are early in our development efforts. Our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, obtain marketing approval, and ultimately commercialize them40% rewritten
2. 09Our business is highly dependent on the success of our lead product candidate, CNTY-813 and our other product candidates52% rewritten
3. 10Our business depends upon the success of our iPSC-derived allogeneic cell therapy platforms
4. 11Utilizing genetically engineered iPSC-derived immune cells and beta islet cells represents a novel therapeutic approach, and we must overcome significant challenges in order to develop, commercialize, and manufacture our product candidatesNew
5. 12We have not yet demonstrated long-term stability of cryopreserved iPSC-derived cell therapy productsNew
6. 13Gene-editing is a rapidly developing technology, and our success is dependent upon our ability to effectively utilize this technology in our product candidates and implement future technological advancements in gene-editing73% rewritten
7. 14Although we design our product candidates to reduce the risk of graft-versus-host disease immune rejection and other immune-mediated complications through gene editing and Allo-Evasion™ technology, such modifications may not be successful in fully mitigating these risksNew
8. 15Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated66% rewritten
9. 16Preclinical and clinical development involve a lengthy and expensive process with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current product candidates or any future product candidates
10. 17Interim, topline, or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data
11. 18We may not be able to file our INDs or CTAs to commence clinical trials on the timelines we expect, and even if we are able to, the FDA or other global health authorities may not permit us to proceed38% rewritten
12. 19We intend to study some of our product candidates in patient populations with significant comorbidities that may result in deaths or serious adverse events or unacceptable side effects and require us to abandon or limit our clinical development activities25% rewritten
13. 20We may experience difficulties identifying and enrolling patients in our future clinical trials. Difficulty in enrolling patients could delay or prevent clinical trials of CNTY-813 or our other product candidates38% rewritten
14. 21We may conduct clinical trials for programs at sites outside the United States, and the FDA may not accept data from trials conducted in such locations. Moreover, conducting clinical trials outside of the United Staes presents additional risks that may delay our trialsNew
15. 22CNTY-813 or our other product candidates may cause adverse events or undesirable side effects that could delay or prevent its regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any48% rewritten
16. 23Public opinion and scrutiny of cell-based and genetically engineered therapies for treating cancer, autoimmune or other serious diseases, or negative clinical trial results from our competitors, may impact public perception of our company and product candidates, or impair our ability to conduct our business42% rewritten
17. 24Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing
18. 25If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our product candidates, if approved, may be delayed
19. 26regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others22% rewritten
20. 27We rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials for our product candidates
21. 28We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
22. 29We may explore strategic collaborations that may never materialize or we may be required to relinquish important rights to and control over the development and commercialization of our product candidates to any future collaborators

Risks related to manufacturing

1. 30The manufacture and distribution of our iPSC-derived cell product candidates is complex and subject to a multitude of risks. These risks could substantially increase our costs and limit the clinical and commercial supply of our product candidates
2. 31There are operational and regulatory risks with manufacturing and releasing product for clinical trials and these could impact our ability to deliver product for trials and therefore impact development timelinesNew
3. 32Delays in commissioning and receiving regulatory approvals for our manufacturing facilities could delay our development plans and thereby limit our ability to generate revenues25% rewritten
4. 33We cryogenically store our engineered cell therapy products, including CAR-iNK cells, CAR-iT cells and iPSC-derived beta islet cells, and master and working cell banks of the engineered iPSC cells at both our own manufacturing facility and at third-party facilitiesNew

Risks related to commercialization of our product candidates

1. 34If we are unable to successfully commercialize CNTY-813 or any of our other product candidates for which we receive regulatory approval, or experience significant delays in doing so, our business will be materially harmed
2. 35We face significant competition, and if our competitors develop product candidates more rapidly than we do or their product candidates are more effective, our ability to develop and successfully commercialize products may be adversely affected50% rewritten
3. 36Companies that compete with us directly on the level of the development of product candidates targeting B-cell lymphomas include but are not limited to Gilead Sciences, Novartis, and Bristol-Myers Squibb, among othersNew
4. 37We expect to face uncertainty regarding the pricing of our existing product candidates and any other product candidates that we may develop, and for which we may receive approval
5. 38The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new products could limit our product revenues
6. 39Even if we obtain regulatory and marketing approval for a product candidate, our product candidates will remain subject to regulatory oversight
7. 40materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws
8. 41Even if we receive marketing approval for CNTY-813 or our other product candidates, we may not achieve broad market acceptance
9. 42Even if we receive marketing approval for CNTY-8131 or our other product candidates in the United States, we may never receive regulatory approval to market CNTY-813 or our other product candidates outside of the United States
10. 43We may be unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market and sell CNTY-813 or our other product candidates, if approved
11. 44If the market opportunities for our product candidates for which we receive marketing approval are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer46% rewritten
12. 45Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide24% rewritten

Risks related to employee matters, managing growth and other risks related to our business

1. 46We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer
2. 47We will need to increase the size and capabilities of our organization, and we may experience difficulties in managing our growth53% rewritten
3. 48We are subject to various foreign, federal, and state healthcare and privacy laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition
4. 49Healthcare legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates59% rewritten
5. 50price controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs and biologics. For additional information on coverage and reimbursement, see the section entitled “Business - Government Regulation - Healthcare reform”New
6. 51If we fail to maintain proper and effective internal controls over financial reporting our ability to produce accurate and timely financial statements could be impaired
7. 52We, or our CMOs or suppliers, may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time-consuming or costly
8. 53If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products
9. 54We may be unable to adequately protect our or our vendors’ information systems from cyberattacks or other incidents, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure
10. 55Our employees and independent contractors, including principal investigators, CROs, consultants, and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
11. 56Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information and personal data
12. 57The increasing use of social media platforms presents new risks and challenges

Risks related to our intellectual property

1. 58We do not currently own issued patents relating to some of our product candidates
2. 59If any of our license agreements with FCDI are terminated, we could lose our rights to key components enabling our iPSC-derived allogeneic cell therapy platforms24% rewritten
3. 60We may not be successful in obtaining or maintaining necessary intellectual property rights in the future for the development of CNTY-813 and our other product candidates
4. 61If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business
5. 62Our success depends on our ability to obtain, maintain, protect, and enforce our intellectual property and our proprietary technologies
6. 63If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected
7. 64The patent protection and patent prosecution for some of our product candidates may be dependent on third parties54% rewritten
8. 65covering CNTY-813 and our other product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using, and selling competing productsNew
9. 66Intellectual property rights do not necessarily address all potential threats to our competitive advantage
10. 67Should any of these events occur, it could significantly harm our business, results of operations, and prospects
11. 68The intellectual property landscape around gene-editing technology is highly dynamic, and third parties may initiate and prevail in legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights
12. 69We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court27% rewritten
13. 70effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplaceNew
14. 71Changes in United States patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect CNTY-813 and our other product candidates
15. 72We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
16. 73Patent terms may be inadequate to protect our competitive position on CNTY-813 and our other product candidates for an adequate amount of time
17. 74If we do not obtain patent term extension for CNTY-813 and our other product candidates, our business may be materially harmed
18. 75We may not be able to protect our intellectual property rights throughout the world
19. 76Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment, and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements
20. 77If we are unable to protect the confidentiality of our trade secrets, our business, and competitive position would be harmed
21. 78We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers

Risks related to our common stock

1. 79The trading price of the shares of our common stock has been highly volatile, and purchasers of our common stock could incur substantial losses31% rewritten
2. 80We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock
3. 81Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall
4. 82We are an emerging growth company and a “smaller reporting company”, and the reduced disclosure requirements applicable to emerging growth companies and “smaller reporting companies” may make our common stock less attractive to investors
5. 83We will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives
6. 84If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline
7. 85Provisions in our corporate charter documents and under Delaware law could discourage another company from acquiring us and may prevent attempts by our stockholders to replace or remove our current management
8. 86We could be subject to securities class action litigation